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A BS TR AC T
BACKGROUND
Two proof-of-concept clinical trials have provided evidence that laquinimod reduces 
disease activity in patients with relapsing–remitting multiple sclerosis.
METHODS
We conducted a randomized, double-blind, phase 3 study at 139 sites in 24 countries. 
A total of 1106 patients with relapsing–remitting multiple sclerosis were randomly 
assigned in a 1:1 ratio to receive oral laquinimod at a dose of 0.6 mg once daily or 
placebo for 24 months. The primary end point was the annualized relapse rate during 
the 24-month period. Secondary end points included confirmed disability progression 
(defined as an increase in the score on the Expanded Disability Status Scale that was 
sustained for at least 3 months) and the cumulative number of gadolinium-enhancing 
lesions and new or enlarging lesions on T2-weighted magnetic resonance imaging.
RESULTS
Treatment with laquinimod as compared with placebo was associated with a modest 
reduction in the mean (±SE) annualized relapse rate (0.30±0.02 vs. 0.39±0.03, P = 0.002) 
and with a reduction in the risk of confirmed disability progression (11.1% vs. 
15.7%; hazard ratio, 0.64; 95% confidence interval, 0.45 to 0.91; P = 0.01). The mean 
cumulative numbers of gadolinium-enhancing lesions and new or enlarging lesions 
on T2-weighted images were lower for patients receiving laquinimod than for those 
receiving placebo (1.33±0.14 vs. 2.12±0.22 and 5.03±0.08 vs. 7.14±0.07, respectively; 
P<0.001 for both comparisons). Transient elevations in alanine aminotransferase 
levels to greater than three times the upper limit of the normal range were observed 
in 24 patients receiving laquinimod (5%) and 8 receiving placebo (2%).
CONCLUSIONS
In this phase 3 study, oral laquinimod administered once daily slowed the progression 
of disability and reduced the rate of relapse in patients with relapsing–remitting 
multiple sclerosis. (Funded by Teva Pharmaceutical Industries; ClinicalTrials.gov 
number, NCT00509145.)
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Laquinimod is an oral quinoline-3-carboxamide small molecule selected for its efficacy and safety from a pool of 60 quino-
line-3-carboxamide derivatives of the parent com-
pound, roquinimex, a drug previously evaluated in 
phase 2 trials of treatment for multiple sclerosis 
but withdrawn because of safety concerns.1 Pre-
clinical studies have shown that laquinimod re-
duces inflammatory cell infiltrates in the central 
nervous system, decreases demyelination, and pre-
vents axonal loss.2 It is currently in clinical devel-
opment for the treatment of multiple sclerosis.3-7 
A 36-week, double-blind, placebo-controlled, phase 
2 clinical trial showed a significant reduction in 
the primary end point, the cumulative number of 
gadolinium-enhancing lesions on magnetic res-
onance imaging (MRI), and also reductions in 
secondary MRI end points for patients receiving 
0.6 mg of laquinimod, as compared with those 
receiving placebo.3
Here we report results from the Assessment of 
Oral Laquinimod in Preventing Progression in Mul-
tiple Sclerosis (ALLEGRO) trial, a 24-month, dou-
ble-blind, randomized, placebo-controlled, phase 
3 study that was designed to evaluate the safety, 
efficacy, and tolerability of oral laquinimod at a 
dose of 0.6 mg administered once daily in patients 
with relapsing–remitting multiple sclerosis.
ME THODS
STUDY OVERSIGHT
The steering committee, in collaboration with the 
sponsor, Teva Pharmaceutical Industries, designed 
and monitored the study. The data and safety mon-
itoring committee periodically reviewed the safety 
and efficacy data. The committee members are 
listed in the Supplementary Appendix, available 
with the full text of this article at NEJM.org. The 
data were collected and analyzed by the sponsor. 
All authors signed confidentiality agreements with 
the sponsor, had full access to the data, and vouch 
for the completeness and accuracy of the data anal-
yses and interpretation. An independent medical-
writing-services agency, paid by the sponsor, wrote 
the first draft of the Methods and Results sections 
of this article, the first author wrote the first draft 
of the introduction and the Discussion section, and 
all authors reviewed the first and subsequent drafts 
of the manuscript. All the authors made the deci-
sion to submit the manuscript for publication. The 
study was conducted according to the protocol, 
which is available at NEJM.org.
PATIENTS
Patients were recruited from 139 sites in 24 coun-
tries (see the Supplementary Appendix for enroll-
ment data by country). Recruitment was initiated 
in November 2007 and lasted 1 year. Eligibility 
criteria included a diagnosis of multiple sclerosis 
(according to the 2005 revised McDonald criteria8) 
with a relapsing–remitting course, an age of 18 
to 55 years, a score of no more than 5.5 on the 
Kurtzke Expanded Disability Status Scale (EDSS, 
which ranges from 0 to 10, with higher scores in-
dicating more severe disability),9 and a disease du-
ration of at least 6 months before screening. Pa-
tients who had not received previous treatment or 
who had received disease-modifying agents were 
eligible if they had had one or more documented 
relapses in the 12 months before screening, two or 
more documented relapses in the 24 months be-
fore screening, or one documented relapse be-
tween 12 and 24 months before screening with at 
least one gadolinium-enhancing lesion in the 
previous year.
Patients were excluded if they had progressive 
forms of multiple sclerosis, an onset of relapse or 
receipt of any glucocorticoid treatment between 
screening and the baseline visit, or clinically sig-
nificant or unstable medical or surgical conditions 
that would preclude safe and complete participa-
tion in the study. Additional exclusion criteria were 
use of investigative drugs or immunosuppressive 
agents (including mitoxantrone) within 6 months 
before screening; use of glatiramer acetate, any 
interferon, or intravenous immune globulin 
within 2 months before screening; use of gluco-
corticoids for at least 30 days within 2 months 
before screening; any previous use of natalizu-
mab, cladribine, or laquinimod; and use of inhibi-
tors of CYP3A4 within 2 weeks before the base-
line visit.
As part of informed consent, the patients were 
informed of the available treatments. They pro-
vided written informed consent before participat-
ing in any study procedure, and they were asked 
to sign an additional informed-consent form after 
a relapse or confirmed disability progression (as 
measured by an increase of 2.0 or more points on 
the EDSS that was sustained for 3 months). The 
protocol was approved by all local institutional 
review boards before initiation of the study.
STUDY DESIGN
Patients were randomly assigned in a 1:1 ratio to 
receive an oral laquinimod capsule at a dose of 
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0.6 mg once daily or a matching placebo capsule. 
The randomization list, stratified according to 
study center, was computer-generated by the sta-
tistical data management department of the spon-
sor. Patients and investigators were unaware of the 
study assignments.
Patients underwent 12 scheduled assessments 
at the study sites during the double-blind phase of 
the study: at screening, at baseline, and at months 
1, 2, 3, 6, 9, 12, 15, 18, 21, and 24. EDSS scores 
were assessed every 3 months. Multiple Sclerosis 
Functional Composite (MSFC) scores were as-
sessed every 6 months. The MSFC score is the aver-
age of the scores on the 9-hole peg test, the timed 
25-ft walk, and the paced auditory serial-addition 
test with a 3-second interval between stimuli, with 
each score converted to a z score; higher scores 
reflect improvement.10 MRI was performed annu-
ally in all patients.
Patients who discontinued the study during 
the double-blind phase underwent a final assess-
ment at the time of discontinuation, with no fur-
ther evaluation, except for those who discontinued 
the study owing to adverse events. Patients com-
pleting the 24-month study were given the oppor-
tunity to join an open-label study extension.
STUDY PROCEDURES AND END POINTS
Efficacy Measures
Neurologic evaluations, including safety assess-
ments, were performed at screening, at baseline, 
and every 3 months until month 24. Neurologic 
assessments and general medical evaluations were 
conducted by two neurologists in order to mini-
mize the possibility of unblinding: an examining 
neurologist with special training and certification 
(www.neurostatus.net) assessed neurologic condi-
tion, and the treating neurologist determined, on 
the basis of the EDSS score, whether a patient had 
a relapse.
The primary end point was the number of con-
firmed relapses during the double-blind study pe-
riod. A relapse was defined as the appearance of 
one or more new neurologic abnormalities or 
the reappearance of one or more previously ob-
served neurologic abnormalities lasting for at 
least 48 hours and occurring after an improved 
neurologic state for at least 30 days. An event was 
counted as a relapse if the patient’s symptoms were 
accompanied by objective neurologic changes as 
indicated by at least one of the following: an in-
crease of at least 0.5 points in the EDSS score, an 
increase of one grade in two or more of the seven 
functional systems that are graded in the EDSS 
(pyramidal, cerebellar, brain stem, sensory, bowel 
and bladder, visual, and cerebral),9 or an increase 
of two grades in one functional system. The stan-
dard treatment of relapses was intravenous admin-
istration of methylprednisolone at a dose of 1 g 
per day for up to 5 consecutive days. Decisions 
regarding both hospitalization and treatment with 
glucocorticoids were made at the discretion of 
the treating neurologist, who was unaware of the 
study-group assignment.
Secondary end points were disability progres-
sion as measured by scores on the EDSS9 and the 
MSFC.10 Confirmed disability progression was 
defined as an increase in the EDSS score of at 
least 1.0 point from baseline if the baseline score 
was between 0 and 5.0 or an increase of at least 
0.5 points if the baseline score was 5.5. To con-
firm disability progression, these increases had to 
be sustained for at least 3 months. Additional 
predefined disability end points are listed in the 
Supplementary Appendix.
For the MSFC, the measure was the total z score 
at 24 months, and the analysis included the scores 
of all patients who completed the double-blind 
phase or discontinued the study after the 12-month 
visit. Additional information on the MSFC is avail-
able in the Supplementary Appendix.
Secondary MRI end points were the cumulative 
number of gadolinium-enhancing lesions at 12 
and 24 months (i.e., the sum of all gadolinium-
enhancing lesions on scans at 12 months plus 
all gadolinium-enhancing lesions on scans at 
24 months) and the cumulative number of new 
or enlarged lesions on T2-weighted images (>50% 
increase from the previous scan) at 12 and 24 
months (i.e., the sum of all new or enlarged 
lesions on T2-weighted images at 12 months plus 
all new or enlarged lesions on T2-weighted im-
ages at 24 months). Exploratory MRI end points 
included the percent change in brain volume, 
measured with the use of the Structural Image 
Evaluation, Using Normalisation, of Atrophy 
(SIENA) and Cross-Sectional Structural Image Eval-
uation, Using Normalisation, of Atrophy (SIENAX) 
programs (version 2.3; FSL Release 3.2).11 Ad-
ditional methodologic details of the MRI assess-
ments are available in the Supplementary Ap-
pendix.
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Table 1. Clinical and Demographic Characteristics of the Study Participants 
at Baseline.*
Characteristic
Laquinimod
(N = 550)
Placebo
(N = 556)
Women — no. (%) 391 (71.1) 368 (66.2)
Age — yr 38.9±9.2 38.5±9.1
Relapses — no.
Within 1 yr before screening 1.2±0.7 1.3±0.7
Within 2 yr before screening 1.9±1.0 1.9±1.0
EDSS score† 2.6±1.3 2.6±1.3
Time from first MS symptom to screening 
— yr
8.7±6.9 8.7±6.7
Previous use of disease-modifying treatment 
— no. (%)‡
210 (38.2) 221 (39.7)
Any interferon§ 209 (38.0) 208 (37.4)
Glatiramer acetate 84 (15.3) 89 (16.0)
Other¶ 35 (6.4) 39 (7.0)
Gadolinium-enhancing lesions — no. 1.7±3.9 2.0±5.7
Volume of lesions on T2-weighted images 
— cm3
9.8±10.4 9.7±10.5
Normalized brain volume — cm3 1578.9±94.3 1584.7±92.1
* Plus–minus values are means ±SD. There were no significant differences be-
tween the two groups in clinical or demographic characteristics. MS denotes 
multiple sclerosis.
† Scores on the Expanded Disability Status Scale (EDSS) range from 0 to 10, 
with higher scores indicating greater disability.
‡ Patients may have received more than one disease-modifying treatment be-
fore enrollment in the study.
§ For specific interferons, the numbers of patients are as follows: interferon  
beta-1b, 76 patients in the laquinimod group and 82 in the placebo group;  
interferon beta-1a, 133 and 123, respectively; and interferon, 0 and 3.
¶ Other disease-modifying treatments included antineoplastic agents (17 pa-
tients in the laquinimod group and 14 in the placebo group), immune globu-
lin or immune serum (5 and 4, respectively), and immunosuppressive agents 
(13 and 21).
Safety and Adverse Events
Safety assessments included measurement of vital 
signs and weight, physical examination, electro-
cardiography, clinical laboratory tests, and record-
ing of adverse events. Adverse-event analysis was 
based on the percentage of patients who discontin-
ued the study and the percentage of patients who 
discontinued the study owing to adverse events.
STATISTICAL ANALYSIS
We estimated that a sample of 1000 patients 
(500 per study group) would provide 90% power to 
detect a significant change in the annualized re-
lapse rate, assuming an expected annualized re-
lapse rate of 0.65 among untreated patients, a 25% 
or greater reduction in the annualized relapse rate 
with laquinimod as compared with placebo, and a 
20% rate of withdrawal from the study over a pe-
riod of 24 months. Clinical and demographic char-
acteristics and safety variables for all patients who 
underwent randomization were summarized with 
the use of descriptive statistics. Time to withdrawal 
was evaluated on the basis of Kaplan–Meier curves.
Using Poisson regression with the study group 
as a covariate, we calculated the annualized re-
lapse rate for the intention-to-treat cohort as the 
total number of confirmed relapses for all pa-
tients in each group, divided by the total patient-
years in that group. In addition to the study 
group, we included as covariates the EDSS score 
at baseline, the log of the sum of 1 plus the 
number of relapses that occurred in the previous 
2 years, and the country or geographic region.
To control for a type 1 error, the secondary end 
points were analyzed only after a significant effect 
was found for the primary end point. Likewise, the 
study’s overall type 1 error was further controlled 
in the analysis of the secondary end points by ap-
plication of the following gatekeeping approach: 
the cumulative number of new or enlarged lesions 
on T2-weighted images and the cumulative number 
of gadolinium-enhancing lesions at 12 months and 
at 24 months were tested simultaneously and the 
between-group difference for both end points had 
to be significant at an alpha level of 0.05, or the 
difference for one of the two end points had to be 
significant at an alpha level of 0.025, if the dif-
ference for the other end point was not significant 
at the 0.05 level. If the above condition was met, 
we proceeded to the analysis of the end point for 
confirmed disability progression; if this end point 
was significant at the 0.05 level, the analysis was 
performed for the total MSFC z scores. Additional 
methodologic details for the statistical analyses are 
included in the Statistical Analysis Plan in the 
Supplementary Appendix.
R ESULT S
STUDY POPULATION
Of the 1106 patients who underwent randomiza-
tion, 550 were assigned to the laquinimod group 
and 556 to the placebo group. A total of 437 pa-
tients (79.5%) in the laquinimod group and 427 
(76.8%) in the placebo group completed the 
24-month study treatment. Of the 1106 patients, 
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Table 2. Clinical and MRI End Points.*
End Point
Laquinimod
(N = 550)
Placebo
(N = 556) P Value
Relapse
Annualized relapse rate
Adjusted mean 0.30±0.02 0.39±0.03 0.002†
Risk ratio (95% CI) 0.77 (0.65 to 0.91)
Relapse-free during study
Adjusted proportion (%) 62.90 52.24 <0.001‡
Odds ratio (95% CI) 1.55 (1.20 to 1.99)
Annualized rate of relapses requiring hospitalization or IV 
glucocorticoids
Adjusted mean 0.24±0.02 0.33±0.02 <0.001†
Risk ratio (95% CI) 0.72 (0.61 to 0.86)
Disability
Risk of disability progression confirmed at 3 mo
Hazard ratio (95% CI) 0.64 (0.45 to 0.91) 0.01§
Patients with confirmed disability progression (%) 11.1 15.7
Risk of disability progression confirmed at 6 mo
Hazard ratio (95% CI) 0.51 (0.34 to 0.79) 0.002§
MSFC — total z score at 24 mo, including discontinuation  
after 12 mo¶
Mean (95% CI) 0.06 (0.00 to 0.11) 0.04 (−0.02 to 0.09) 0.59‖
Lesion activity on brain MRI
Cumulative no. of gadolinium-enhancing lesions  
at 12 and 24 mo
Mean 1.33±0.14 2.12±0.22 <0.001**
Rate ratio (95% CI) 0.63 (0.49 to 0.81)
Cumulative no. of new or enlarged lesions on T2-weighted 
images at 12 and 24 mo
Mean 5.03±0.08 7.14±0.07 <0.001**
Rate ratio (95% CI) 0.70 (0.58 to 0.85)
Change in brain volume from baseline to 24 mo
Adjusted mean percent change −0.87 −1.30 <0.001††
Adjusted mean percentage-point difference (95% CI) 0.43 (0.27 to 0.59)
*  Plus–minus values are means ±SE. IV denotes intravenous.
†  The P value was calculated with the use of a quasi-likelihood (overdispersed) Poisson regression analysis, with adjust-
ment for EDSS score at baseline, log of the sum of 1 plus the number of relapses in the previous 2 years, and country 
or geographic region.
‡  The P value was calculated with the use of a logistic-regression analysis, with adjustment for baseline EDSS score, 
natural log of the sum of 1 plus the number of relapses in the previous 2 years, and country or geographic region.
§  The P value was calculated with the use of a Cox model regression analysis, with adjustment for baseline EDSS score, 
log of the sum of 1 plus the number of relapses in the previous 2 years, and country or geographic region.
¶  The Multiple Sclerosis Functional Composite (MSFC) is the average of scores on the 9-hole peg test, the timed 25-ft 
walk, and the paced auditory serial-addition test with a 3-second interval between stimuli, with each converted to a  
z score; higher scores reflect improvement.
‖  The P value was calculated with the use of an analysis of covariance, with adjustment for baseline MSFC score as a 
1-degree-of-freedom covariate and baseline EDSS score, log of the sum of 1 plus the number of relapses in the previ-
ous 2 years, and country or geographic region as covariates.
** The P value was calculated with the use of a negative binomial regression model, with adjustment for number of  
gadolinium-enhancing lesions at baseline and country or geographic region and with an offset to adjust for absence 
of exposure to study treatment owing to early discontinuation.
†† The P value was calculated with the use of analysis of covariance, with adjustment for number of gadolinium-enhancing 
lesions at baseline and the country or geographic region.
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13.7% discontinued the study during the first year 
(12.0% in the laquinimod group and 15.2% in the 
placebo group), and an additional 8.2% discontin-
ued the study during the second year (8.5% and 
7.9%, respectively). Reasons for discontinuation of 
the study are shown in Figure 1 in the Supplemen-
tary Appendix. The most common reasons for dis-
continuation were the patient’s decision not to sign 
the additional informed-consent form and with-
drawal of consent after one relapse (8.0% of pa-
tients in the laquinimod group and 10.8% in the 
placebo group). The clinical and demographic 
characteristics of the study groups at baseline were 
well balanced (Table 1).
RELAPSE END POINTS
The mean (±SD) annualized relapse rate during 
the 24-month treatment period (primary outcome) 
was significantly reduced in the laquinimod 
group as compared with the placebo group 
(0.30±0.02 vs. 0.39±0.03, P = 0.002) (Table 2). In 
exploratory analyses that were prespecified in the 
protocol, the percentage of patients who were re-
lapse-free was 62.9% in the laquinimod group 
(346 of 550 patients) and 52.2% in the placebo 
group (290 of 556, P<0.001); the time to the first 
relapse during the study was longer for patients 
receiving laquinimod than for those receiving 
placebo, and the risk of relapse was significantly 
reduced with laquinimod (hazard ratio, 0.72; 
95% confidence interval, 0.59 to 0.87; P<0.001). 
In an additional prespecified exploratory analy-
sis, the annualized rate of relapse requiring hos-
pitalization or intravenous treatment with gluco-
corticoids, according to the treating neurologist’s 
decision, was significantly lower among patients 
receiving laquinimod as compared with those re-
ceiving placebo (0.24 vs. 0.33, P<0.001).
DISABILITY END POINTS
The risk of disability progression as assessed by 
an increase in EDSS scores that was sustained for 
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Figure 1. Clinical Outcomes and MRI Measures 
of Efficacy According to Study Group.
Panel A shows the number of confirmed relapses. Panel 
B shows the Kaplan–Meier plot for the risk of disability 
progression that was confirmed after 3 months, as 
measured by scores on the Expanded Disability Status 
Scale. Panel C shows the adjusted mean number of 
gadolinium-enhancing lesions at baseline, at 12 months, 
and at 24 months and the cumulative number at  
24 months. T bars indicate standard errors.
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3 months (secondary outcome) was significantly 
decreased for patients receiving laquinimod, as 
compared with those receiving placebo (11.1% vs. 
15.7%; hazard ratio, 0.64; P = 0.01) (Fig. 1B). This 
observation was reinforced by two findings from 
additional analyses: the risk of confirmed pro-
gression was significantly reduced with the use of 
the more stringent approach, which required the 
persistence of the change in the EDSS score at the 
last available assessment (hazard ratio with la-
quinimod, 0.66; P = 0.04), and the actual propor-
tion of patients with confirmed disability pro-
gression at the last assessment was lower in the 
laquinimod group than in the placebo group 
(9.8% [54 of 550 patients] vs. 14.0% [78 of 556], 
P = 0.04). The mean EDSS scores at the last assess-
ment were 2.68 and 2.79 in the laquinimod and 
placebo groups, respectively (P = 0.05). In an anal-
ysis that was not prespecified in the protocol but 
was designed before the initiation of data analyses, 
there was a decrease in the risk of confirmed dis-
ability progression at 6 months with laquinimod 
(hazard ratio, 0.52; P = 0.002). There was little over-
all change in the MSFC scores from baseline to 
24 months (secondary outcome), and the adjusted 
mean total MSFC z score at 24 months did not 
differ significantly between the laquinimod group 
and the placebo group (0.06 and 0.04, respec-
tively; P = 0.59).
MRI END POINTS
Laquinimod reduced the mean cumulative num-
ber of gadolinium-enhancing lesions (secondary 
outcome), as compared with placebo (rate ratio, 
Table 3. Serious Adverse Events, Adverse Events, and Elevated Liver-Enzyme Levels.*
Event
Laquinimod
(N = 550)
Placebo
(N = 556) Risk Ratio
Serious adverse events — no. of events (% of patients  
with ≥1 event)
Diarrhea 2 (0.4) 0
Vomiting 3 (0.2) 0
Fever 2 (0.4) 0
Peripheral edema 2 (0.4) 0
Appendicitis 5 (0.9) 1 (0.2)
Cellulitis 2 (0.4) 1 (0.2)
Hypokalemia 2 (0.4) 0
Uterine leiomyoma 2 (0.4) 1 (0.2)
Headache 2 (0.4) 1 (0.2)
Neoplasms — no. of events (% of patients) 8 (1.5) 6 (1.1)
Basal-cell carcinoma 1 (0.2) 1 (0.2)
Breast cancer† 3 (0.5) 1 (0.2)
Malignant lung neoplasm 1 (0.2) 0
Lymphoma 1 (0.2) 0
Esophageal adenocarcinoma‡ 1 (0.2) 0
Ovarian cancer 0 2 (0.4)
Prostate cancer 0 1 (0.2)
Glioblastoma multiforme§ 1 (0.2) 0
Rectal cancer 0 1 (0.2)
Adverse events — no. of events, no. of patients  
(% of patients)
Infection
Urinary tract infection 58, 40 (7.3) 36, 25 (4.5) 1.6
Sinusitis 37, 29 (5.3) 37, 25 (4.5) 1.2
Nervous system disorder — headache 222, 125 (22.7) 173, 99 (17.8) 1.3
Liver-function abnormality — elevated ALT¶ 47, 38 (6.9) 15, 15 (2.7) 2.6
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0.63; P<0.001) (Fig. 1C). The mean cumulative num-
ber of new or enlarged lesions on T2-weighted 
images at 12 and 24 months (secondary outcome) 
was also reduced in the laquinimod group (rate 
ratio, 0.70; P<0.001). In a prespecified exploratory 
analysis, patients receiving laquinimod had a low-
er percentage of brain-volume loss from baseline 
to 24 months, as compared with patients receiving 
placebo (adjusted mean, −0.87% vs. −1.30%; mean 
difference, 0.43 percentage points; P<0.001) (see the 
Supplementary Appendix).
SAFETY PROFILE AND ADVERSE EVENTS
No deaths occurred in the laquinimod group, and 
three deaths occurred in the placebo group (from 
injury, suicide, and complications of pneumonia). 
A total of 122 serious adverse events were reported 
in 11.1% of patients receiving laquinimod (61 of 
550), and 90 were reported in 9.5% of those receiv-
ing placebo (53 of 556); events occurring in at least 
2 patients in the laquinimod group and those oc-
curring at a higher frequency in the laquinimod 
group than in the placebo group are shown in Table 
3. A higher incidence of appendicitis was reported 
in the laquinimod group than in the placebo group 
(5 cases vs. 1). In all cases, an appendectomy was 
performed, without additional complications, and 
the patients continued with the study treatment. 
There were 14 cases of neoplasms (8 in the laquini-
mod group and 6 in the placebo group) with a 
large variation in the type of cancer.
There were 3309 adverse events in the laquini-
mod group and 2965 in the placebo group, with 
87% and 81% of patients, respectively, reporting 
Table 3. (Continued.)
Event
Laquinimod
(N = 550)
Placebo
(N = 556) Risk Ratio
Gastrointestinal disorder
Diarrhea 50, 44 (8.0) 41, 34 (6.1) 1.3
Nausea 39, 34 (6.2) 38, 32 (5.8) 1.1
Abdominal pain 36, 32 (5.8) 16, 16 (2.9) 2.0
Respiratory disorder — cough 46, 41 (7.5) 29, 25 (4.5) 1.7
Musculoskeletal disorder
Back pain 119, 90 (16.4) 73, 50 (9.0) 1.8
Arthralgia 62, 47 (8.5) 49, 42 (7.6) 1.1
Psychiatric disorder — insomnia 40, 36 (6.5) 38, 31 (5.6) 1.2
Elevated ALT — no. of patients/total no. of patients (%)‖
>1 and ≤3× ULN 151/504 (30.0) 91/515 (17.7)
>3 and ≤5× ULN** 18/504 (3.6) 2/515 (0.4)
>5 and ≤8× ULN†† 3/504 (0.6) 3/515 (0.6)
>8× ULN‡‡ 3/504 (0.6) 3/515 (0.6)
*  Serious adverse events reported here are those that occurred in two or more patients in the laquinimod group or oc-
curred more often in the laquinimod group than in the placebo group. Adverse events reported here are those that 
occurred in 5% or more of all patients or that occurred more often in the laquinimod group than in the placebo 
group. ALT denotes alanine aminotransferase, and ULN upper limit of the normal range.
†  One patient had received partial treatment for breast cancer before enrollment in the study; metastases were revealed 
on the same side.
‡  One patient had a history of long-standing esophageal pain before enrollment in the study, which had been attributed 
to depression.
§  A retrospective assessment showed the tumor on the baseline MRI scan.
¶  Data shown are all ALT elevations that were reported as adverse events.
‖  Data shown are all ALT elevations in the specified categories, which were not necessarily reported as adverse events. 
The analysis included only patients who had ALT levels below the upper limit of the normal range at baseline.
** Six patients (1.1%) receiving laquinimod and one receiving placebo (0.1%) discontinued the study because of the 
ALT elevation.
†† The protocol mandated discontinuation of the study if this elevation persisted for 2 weeks; two patients (0.4%) re-
ceiving laquinimod and one (0.2%) receiving placebo discontinued the study.
‡‡ For this elevation, the protocol mandated immediate discontinuation of the study; three patients (0.6%) receiving  
laquinimod and four (0.8%) receiving placebo discontinued the study.
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one or more events. Adverse events that occurred 
in at least 5% of all patients and those that oc-
curred at a higher rate in the laquinimod group 
than in the placebo group are listed in Table 3. 
The three most common adverse events in the la-
quinimod group (excluding elevated levels of liver 
enzymes, discussed below) were abdominal pain 
(in 32 patients [5.8%], vs. 16 [2.9%] in the placebo 
group), back pain (in 90 patients [16.4%] vs. 50 
[9.0%]), and cough (in 41 patients [7.5%] vs. 25 
[4.5%]). These adverse events were rarely associat-
ed with discontinuation of the study (3% and 1% 
of the laquinimod and placebo groups, respec-
tively).
More patients in the laquinimod group than in 
the placebo group had alanine aminotransferase 
levels that were greater than 3 times the upper 
limit of the normal range but less than or equal 
to 5 times the upper limit (18 patients [3.6%] vs. 
2 [0.4%]). In contrast, alanine aminotransferase 
levels that were greater than 5 times the upper 
limit of the normal range occurred equally often in 
the two groups (in 6 patients in each group) and 
led to equal rates of discontinuation. Elevations to 
values that were up to or equal to 5 times the up-
per limit of the normal range usually occurred 
within the first 6 months, and in all cases, they 
were reversible either without discontinuation of 
the study drug or within 2 months after discon-
tinuation. There were no cases of liver failure and 
no cases of concomitant elevations of bilirubin 
levels or coagulation values (Hy’s law, which states 
that an elevation of liver aminotransferases along 
with an elevation of bilirubin is predictive of liver 
failure).12 Elevated levels of alanine aminotransfer-
ase (from 3 to less than 5 times the upper limit of 
the normal range) led to discontinuation in 6 pa-
tients receiving laquinimod and in 1 receiving 
placebo.
DISCUSSION
The ALLEGRO study showed that, as compared 
with placebo, laquinimod significantly but mod-
estly reduced the annualized rate of relapse of 
multiple sclerosis in a manner consistent with its 
suppression of inflammatory disease activity, as 
measured by MRI. Laquinimod was also associat-
ed with a significant reduction in the risk of con-
firmed progression of disability. We did not detect 
significant between-group differences in the MSFC 
scores. The significant reduction in the explor-
atory end point of the percent change in brain 
volume, as measured by MRI, in this study is an 
interesting corollary to the effect on disability 
progression.
Elevated levels of liver enzymes occurred 2 times 
more frequently in the laquinimod group. These 
elevations were transient and were not associated 
with clinical, imaging, or laboratory signs of liver 
failure. Abdominal pain occurred more frequently 
in the patients who received laquinimod than in 
those who received placebo; however, it was rarely 
a reason for discontinuation of the study treat-
ment. It is worth noting that the safety concerns 
previously seen with roquinimex,13 such as sero-
sitis, cardiovascular events, and thrombosis, did 
not emerge as signals in the current study. Al-
though long-term studies are needed to adequate-
ly assess the risk of infections and cancers, we did 
not observe increased rates of these serious ad-
verse events. An open-label extension of the study, 
involving 844 of the 864 patients who completed 
the study, is ongoing. The data and safety moni-
toring committee has not reported any new safety 
signals so far in this extension study.
In conclusion, we found that laquinimod, as 
compared with placebo, reduced the rate of relapse 
and slowed the progression of disability in patients 
with relapsing–remitting multiple sclerosis.
Supported by Teva Pharmaceutical Industries.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank the patients who participated in the study; the inde-
pendent data and safety monitoring committee; members of the 
MRI Analysis Center; the principal investigators in each country 
(see the Supplementary Appendix for a complete list); Dan Bar-
Zohar, M.D., and Nora Tarcic, Ph.D., of the Teva Innovative Re-
search and Development Clinical Team (Netanya, Israel) for 
participating in the development and monitoring of the study; 
Nissim Sasson, M.A., of the Teva Statistical Data Management 
Team (Netanya) for managing the statistical analyses, and the 
other members of his team — Yossi Levy, Ph.D., Eli Eyal, M.Sc., 
Maya Ben Lassan, B.A., Adam Carlquist, B.A., and Eitan Horev, 
M.B.A.; and Pippa Loupe, Ph.D., of Medical Affairs, Teva Phar-
maceuticals (Kansas City, MO), and James D. Bergstrom, Ph.D., 
of Mountain Stream Communications (Hillsborough, NJ) for 
participating in the writing and editing of the manuscript.
The New England Journal of Medicine 
Downloaded from nejm.org on January 31, 2019. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
Or al Laquinimod for Multiple Sclerosis
n engl j med 366;11 nejm.org march 15, 2012 1009
REFERENCES
nejm 200th anniversary articles
The NEJM 200th Anniversary celebration includes publication of a series  
of invited review and Perspective articles throughout 2012.  
Each article explores a story of progress in medicine over the past 200 years.  
The collection of articles is available at the NEJM 200th Anniversary website,  
http://NEJM200.NEJM.org.
1. Jönsson S, Andersson G, Fex T, et al. 
Synthesis and biological evaluation of 
new 1,2-dihydro-4-hydroxy-2-oxo-3 quin-
olinecarboxamides for treatment of auto-
immune disorders: structure–activity re-
lationship. J Med Chem 2004;47:2075-88.
2. Brück W, Wegner C. Insight into the 
mechanism of laquinimod action. J Neurol 
Sci 2011;306:173-9.
3. Comi G, Pulizzi A, Rovaris M, et al. 
Effect of laquinimod on MRI-monitored 
disease activity in patients with relapsing-
remitting multiple sclerosis: a multicen-
tre, randomised, double-blind, placebo-
controlled phase IIb study. Lancet 2008; 
371:2085-92.
4. Comi G, Abramsky O, Arbizu T, et al. 
Oral laquinimod in patients with relaps-
ing-remitting multiple sclerosis: 36-week 
double-blind active extension of the 
multi-centre, randomized, double-blind, 
parallel-group placebo-controlled study. 
Mult Scler 2010;16:1360-6.
5. Comi G, Abramsky O, Arbizu T, et al. 
Long-term open extension of oral la-
quinimod in patients with relapsing 
multiple sclerosis shows favorable safety 
and sustained low relapse rate and MRI 
activity. Mult Scler 2009;15:Suppl 2:S127. 
abstract.
6. Polman C, Barkhof F, Sandberg-Woll-
heim M, Linde A, Nordle O, Nederman T. 
Treatment with laquinimod reduces de-
velopment of active MRI lesions in relaps-
ing MS. Neurology 2005;64:987-91.
7. Preiningerova J. Oral laquinimod ther-
apy in relapsing multiple sclerosis. Expert 
Opin Investig Drugs 2009;18:985-9.
8. Polman CH, Reingold SC, Edan G, et al. 
Diagnostic criteria for multiple sclerosis: 
2005 revisions to the “McDonald Criteria.” 
Ann Neurol 2005;58:840-6.
9. Kurtzke JF. Rating neurologic impair-
ment in multiple sclerosis: an Expanded 
Disability Status Scale (EDSS). Neurology 
1983;33:1444-52.
10. Cutter GR, Baier ML, Rudick RA, et al. 
Development of a multiple sclerosis func-
tional composite as a clinical trial out-
come measure. Brain 1999;122:871-82.
11. SIENA and SIENAX. Oxford, United 
Kingdom: FMRIB Software Library (http:// 
www.fmrib.ox.ac.uk/analysis/research/ 
siena/siena).
12. Temple R. Hy’s law: predicting serious 
hepatotoxicity. Pharmacoepidemiol Drug 
Saf 2006;15:241-3.
13. Noseworthy JH, Wolinsky JS, Lublin 
FD, et al. Linomide in relapsing and sec-
ondary progressive MS. Part 1: trial design 
and clinical results. Neurology 2000;54: 
1726-33.
Copyright © 2012 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org on January 31, 2019. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
